Skip to main content
KoBioLabs, Inc. logo

KoBioLabs, Inc. — Investor Relations & Filings

Ticker · 348150 ISIN · KR7348150004 KO Manufacturing
Open in API
Filings indexed 174 across all filing types
Latest filing 2021-10-08 Director's Dealing
Country KR South Korea
Listing KO 348150

About KoBioLabs, Inc.

http://kobiolabs.com/en/

KoBioLabs, Inc. is a biotechnology company that develops innovative microbiome-based therapeutics. The company utilizes its proprietary Smartiome® platform, an integrated system for discovering novel drug candidates that employs AI-driven multi-omics analysis and a comprehensive microbiome library with a reverse-translation approach. KoBioLabs is focused on creating a pipeline of new drugs to treat a range of immune, metabolic, and brain disorders. The company also applies advanced technologies, including a microbe-based drug delivery system (mDDS) and biofoundry techniques, to enhance the efficacy of its treatments and address unmet medical needs.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used by executives and major shareholders to report their shareholdings and changes in ownership (insider trading/holdings). In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2021-10-08 Korean
기타경영사항(특허권취득)(자율공시)(락토바실러스 크리스파투스 KBL693 균주 및 그 용도)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by the company '고바이오랩'. It details the patent name, content, and utilization plan. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, M&A, or governance categories, it falls under the general regulatory announcement category.
2021-09-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. This type of filing is specifically used to report changes in significant share ownership (crossing thresholds or changes in special relationships) as required by the Capital Markets Act. In the provided taxonomy, 'Major Shareholding Notification' (MRQ) is the correct category for filings that disclose changes in significant share ownership levels.
2021-09-06 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific individuals, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding the issuance of new rights or capital-related instruments falls under the category of share issuance or capital changes.
2021-08-18 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'KoBioLabs' (고바이오랩) covering the period from January 1, 2021, to June 30, 2021. It contains detailed financial information, business operations, management discussions, and corporate governance details. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2021
2021-08-17 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to an executive, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation is classified as a regulatory filing under the 'RNS' category as it does not fit into specific categories like 'DIRS' (which is for personal trades by directors) or 'SHA' (which is for general share issuance/capital changes).
2021-07-21 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.